Orchestra BioMed Hldgs Analyst Ratings
Orchestra BioMed Hldgs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 261.01% | Chardan Capital | → $20 | Reiterates | Buy → Buy |
| 05/15/2023 | 261.01% | Chardan Capital | → $20 | Reiterates | Buy → Buy |
| 02/24/2023 | 170.76% | Piper Sandler | → $15 | Initiates Coverage On | → Overweight |
| 02/07/2023 | 261.01% | Chardan Capital | → $20 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/09/2023 | 261.01% | 查丹資本 | → 20 美元 | 重申 | 購買 → 購買 |
| 05/15/2023 | 261.01% | 查丹資本 | → 20 美元 | 重申 | 購買 → 購買 |
| 02/24/2023 | 170.76% | 派珀·桑德勒 | → 15 美元 | 啓動覆蓋開啓 | → 超重 |
| 02/07/2023 | 261.01% | 查丹資本 | → 20 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Orchestra BioMed Hldgs (OBIO)?
Orchestra BioMed Hldgs（OBIO）的目標價格是多少？
The latest price target for Orchestra BioMed Hldgs (NASDAQ: OBIO) was reported by Chardan Capital on August 9, 2023. The analyst firm set a price target for $20.00 expecting OBIO to rise to within 12 months (a possible 261.01% upside). 4 analyst firms have reported ratings in the last year.
Chardan Capital於2023年8月9日公佈了Orchestra BioMed Hldgs（納斯達克股票代碼：OBIO）的最新目標股價。這家分析公司將目標股價定爲20.00美元，預計OBIO將在12個月內升至20.00美元（可能上漲261.01％）。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Orchestra BioMed Hldgs (OBIO)?
Orchestra BioMed Hldgs（OBIO）的最新分析師評級是多少？
The latest analyst rating for Orchestra BioMed Hldgs (NASDAQ: OBIO) was provided by Chardan Capital, and Orchestra BioMed Hldgs reiterated their buy rating.
Orchestra BioMed Hldgs（納斯達克股票代碼：OBIO）的最新分析師評級由Chardan Capital提供，Orchestra BioMed Hldgs重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Orchestra BioMed Hldgs (OBIO)?
Orchestra BioMed Hldgs（OBIO）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Orchestra BioMed Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Orchestra BioMed Hldgs was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Orchestra BioMed Hldgs的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Orchestra BioMed Hldgs的最後評級是在2023年8月9日提交的，因此你應該預計下一個評級將在2024年8月9日左右公佈。
Is the Analyst Rating Orchestra BioMed Hldgs (OBIO) correct?
分析師評級 Orchestra BioMed Hldgs (OBIO) 正確嗎？
While ratings are subjective and will change, the latest Orchestra BioMed Hldgs (OBIO) rating was a reiterated with a price target of $0.00 to $20.00. The current price Orchestra BioMed Hldgs (OBIO) is trading at is $5.54, which is within the analyst's predicted range.
儘管收視率是主觀的，將會發生變化，但最新的Orchestra BioMed Hldgs（OBIO）評級得到了重申，目標股價爲0.00美元至20.00美元。Orchestra BioMed Hldgs（OBIO）目前的交易價格爲5.54美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。